Tebapivat by Agios Pharmaceuticals for Sickle Cell Disease: Likelihood of Approval

Tebapivat is under clinical development by Agios Pharmaceuticals and currently in Phase I for Sickle Cell Disease.

FDA loosens side effect reporting requirements for some CAR-T therapies

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 19, 2024

Clearmind Medicine: New Scientific Publication Shows MEAI’s Potential as a Novel Weight Loss Drug | Psychedelic Invest

Vancouver, Canada, Aug. 06, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of

August 7, 2024

Changes in prescribing practices and parental awareness contribute to teen drug decline

Since 2009, U.S. high school seniors have reported steep declines in medical use, misuse and availability of the three most commonly prescribed and misused controlled

July 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.